Resources
I had the privilege of entering the tech transfer profession in its very early days. We had many questions about whether technology transfer even had a sustainable business model. I had the opportunity to research and try to address many of the issues we came across, working with colleagues around the world.
Here you will find some of my writings and teachings on some of the issues I had the privilege of addressing.
- Innovation
- Global Health
- Start Ups
- Technology Transfer in Emerging Economies
- Technology Valuation
- Technology Transfer Practice
- The Bayh-Dole act
- The Economic Impact of Technology Transfer
Publications |
Presentations |
Global Patterns of Innovation in 2013 |
|
The Enactment of Bayh-Dole |
The Bayh-Dole Act – History and Impact |
The Bayh-Dole Act Turns 30 |
Lessons Learned from Three Decades of University IP and Technology Transfer --Perspectives from the United States of America |
Understanding the Importance of Bayh-Dole |
|
How Are U.S. Technology Transfer Offices Tasked -- Is It All About the Money |
How are U.S. Academic Licensing Offices Tasked and Motivated? |
Using Academic License Agreements to Promote Global Social Responsibility |
Socially Responsible Licensing of Drugs and Vaccines |
Technology Transfer’s Twenty-Five Percent Rule |
6th Annual Conference on Collaboration for Advancing Entrepreneurship: Academia’s 25% Rule |
The Role of Patents and Commercialization in the Tenure and Promotion Process |
|
The Role of Public-Sector Research in the Discovery of New Drugs and Vaccines -- Appendix |
|
Technology Transfer and its Role in the Practice of Reproductive Endocrinology and Infertility |
|
20 Years of Academic Licensing -- Income and Economic Impact |
Great University Inventions |
The Role of Public-Sector Research in the Discovery of New Drugs and Vaccines |
Measuring Economic Impact |
The Biopharmaceutical Industry in Massachusetts -- the Triple Helix in Action |
The Role of Public Sector Research in the Discovery of Drugs and Vaccines |
The Commercialization of New Drugs and Vaccines Discovered in Public Sector Research |
Benefits of IP-based Technology Transfer for the University, its Stakeholders, and Society at Large |
What is the Total Economic Impact of Academic Technology Transfer |
|
Risk-adjusted Net Present Value -- A New Way to Value Early Stage Technologies |
Sublicense Income Sharing |
Valuation in Global Health Licenses |
|
Finding Comparable Licenses |
|
Defining Sublicense Income To Avoid Problems Down the Road |
|
Intellectual Property Valuation Manual for Academic Institutions |
|
An Emerging Model for Life Sciences Commercialization |
Challenges in Implementing the Triple Helix in the Developing World |
|
Important Issues Regarding Technology Transfer Office Funding and Operations |
|
The University as a Participant in the Innovation Ecosystem and How Can Governments support it? |
|
Developing and Supporting Associations of Technology Transfer Professionals & Quantitative Assessment |
|
Essential Elements of a Sustainable University IP and Technology Transfer Function |
The Future of Global Health Networks |
Socially Responsible Licensing of Drugs and Vaccines |
Using Academic License Agreements to Promote Global Social Responsibility |
|
Valuation in Global Health Licenses |
|